登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002873 证券简称：新天药业 公告编号：2026-005 贵阳新天药业股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、报告期内，受市场环境等因素影响，公司营业收入较上年同期下降，同时因部分原材料价格上涨， 导致公司的生产成本上升，对当期业绩造成一定影响。 2、2025年度非经常性损益对净利润的影响金额较上年同期下降，主要是2024年度公司处置"盐酸班布特 罗颗粒"药品上市许可及相关生产技术增加净利润约1,600万元。 公司将结合实际，除持续优化经营管理与营销推广策略，提升市场开发的精准度和有效性外，还将充分 利用药材价格分析预判和库存储备调节相结合的策略，减少原材料价格带来的成本增长压力。同时，多 方面提高内部管理效率，促进公司经营管理与盈利能力的改善。 四、风险提示 本次业绩预告是根据公司财务部门初步核算得出，未经审计机构审计，具体财务数据请以公司后续披露 的经审计的2025年年度报告为准。敬请广大投资者谨慎决策，注意投资风险。 1、 ...

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. has signed a drug listing license transfer agreement with Anhui Meilai Pharmaceutical Co., Ltd. for the product Lactulose Oral Solution, which will enhance the company's product pipeline and market competitiveness [2][4][14]. Group 1: Transaction Overview - The agreement involves the transfer of the listing license for Lactulose Oral Solution (15ml:10g) from Anhui Meilai to the company's subsidiary, Guoyao Group Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd., for a total transfer fee of RMB 5.86 million [4][10]. - The transaction does not require approval from the company's board or shareholders and is not classified as a related party transaction [4][14]. Group 2: Parties Involved - Anhui Meilai Pharmaceutical Co., Ltd. is a non-listed company with a registered capital of RMB 25.37 million, established on December 30, 2021, and has no related party relationship with the company or its subsidiary [5][6]. - Guoyao Group Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. is a limited liability company with a registered capital of RMB 50 million, established on July 13, 1990, and is involved in various pharmaceutical and medical services [8]. Group 3: Product Information - Lactulose is an osmotic laxative used for treating chronic functional constipation and has prebiotic effects, helping to balance gut microbiota [9]. - The projected sales for Lactulose Oral Solution in public medical institutions and retail markets in 2024 are estimated at RMB 2.069 billion [9]. Group 4: Agreement Details - The agreement grants the buyer all rights and interests related to the product, including global operational rights and intellectual property rights, with no third-party restrictions [10][11]. - The total transfer fee is RMB 5.86 million, payable in installments based on contract performance milestones [12].

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the transfer of drug marketing authorization for lactulose oral solution from Anhui Meilai to its subsidiary, Guoyao Zhijun Ping Shan, aligns with the company's long-term strategic development plan and aims to enhance its product pipeline in chronic disease treatment [1] Group 1 - The total transfer fee for the drug marketing authorization is RMB 5.86 million [1] - Lactulose is an osmotic laxative primarily used for treating chronic functional constipation and also serves as a prebiotic to regulate gut microbiota [1] - The acquisition of the lactulose oral solution marketing authorization is expected to strengthen Guoyao Zhijun Ping Shan's market competitiveness without significantly impacting the company's current operating performance [1]

Core Viewpoint - The announcement indicates that China National Pharmaceutical Group's subsidiary, Guoyao Zhijun (Pingshan) Pharmaceutical Co., Ltd., has signed a drug listing license transfer contract with Anhui Meilai Pharmaceutical Co., Ltd. for the product Lactulose Oral Solution, which will enhance the company's product line in chronic disease treatment and strengthen its market competitiveness [1] Summary by Relevant Categories Transaction Details - The total transfer fee for the drug listing license is RMB 5.86 million [1] - The product involved in the transfer is Lactulose Oral Solution (15ml:10g) [1] Strategic Implications - The transaction aligns with the company's strategic development plan [1] - It is expected to enrich the company's product line for chronic disease treatment [1] - The deal is anticipated to enhance the market competitiveness of Guoyao Zhijun Pingshan [1] Financial Impact - The transaction will not have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company XinHua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplemental application of Adenosylcobalamin capsules, allowing the transfer of the marketing authorization holder [1] Group 1: Regulatory Approval - The approval notification allows the company to transfer the supplemental application without the need for board or shareholder meeting reviews, in accordance with the Shenzhen Stock Exchange listing rules and the company's articles of association [1] - The transaction does not constitute a related party transaction or a major asset restructuring as defined by the regulations [1] Group 2: Product Indications - Adenosylcobalamin capsules are primarily indicated for the treatment of megaloblastic anemia, nutritional anemia, anemia during pregnancy, multiple neuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve paralysis [1] - The product can also be used as an adjunctive treatment for nutritional disorders and leukopenia caused by radiation and drugs [1]

Group 1 - The company Hunan Fangsheng Pharmaceutical Co., Ltd. has acquired the ownership of 20 registered drug varieties from Kangyi Pharmaceutical Co., Ltd. in Hong Kong [1] - A joint venture company in Hong Kong is to be established with a registered capital of 20 million HKD, where the company will hold 35% initially [1] - The company plans to sign a new drug transfer agreement with Kangyi Pharmaceutical after the establishment of the joint venture [1] Group 2 - Due to regulatory issues regarding foreign investment, the company has adjusted its shareholding structure in the joint venture, increasing its stake from 35% to 50% and raising its investment from 7 million HKD to 10 million HKD [2] - The new shareholding structure includes other parties with varying stakes, ensuring compliance with investment regulations [2][3] - The joint venture will officially sign the investment cooperation agreement to clarify the rights and obligations of all parties involved [3] Group 3 - The adjustment in the shareholding structure of the joint venture is not expected to significantly impact the company's normal operations or financial results [3] - The transfer of drug licenses is still in process and is not affected by the changes in the joint venture [3]